Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Human papillomavirus (HPV) E6 protein is a small oncoprotein expressed by high-risk HPV strains, notably HPV-16 and HPV-18. It plays a central role in the development of cervical cancer by degrading tumor suppressors like p53, activating telomerase, modulating the immune system, and promoting cellular immortalization. E6 interacts with multiple cellular partners, including E6AP, p53, PDZ domain proteins, and BAK, to disrupt normal cell cycle control and promote malignant transformation. Targeting E6 is a major area of research for developing novel therapeutics against HPV-related cancers.
Targeting E6 can restore p53 function, inhibit telomerase activity, and enhance immune recognition of infected cells. Potential mechanisms include inhibiting E6-E6AP interaction or disrupting E6 binding to other cellular targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Papillomavirus E6 Protein (E6).